Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this pharmaceutical company have returned -11.6% over the past month versus the Zacks S&P 500 composite's -6.5% change. The Zacks Large Cap Pharmaceuticals industry, to which Merck belongs, has lost 5.7% over this period. Now the key question is: Where could the stock be headed in the near term?A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 1-6571 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 22-1918501 (State or other jurisdiction of ...

GERMANY - 2024/02/20: In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesMerck (NYSE: MRK) recently reported its Q2 results, with revenues and earnings exceeding our estimates. The company garnered $16.1 billion in revenue and adjusted earnings of $2.28 per share, compared to our estimates of $15.9 billion and $2.20, respectively. The growth was prima ...

Merck & Co Inc MRK reported better-than-expected second-quarter earnings and sales results on Tuesday.The company posted quarterly sales of $16.1 billion, up 7% year-over-year, beating the consensus estimate of $15.84 billion. Excluding the impact of foreign exchange, sales increased 11%. Merck reported adjusted EPS of $2.28, a shift from an EPS loss of $(2.06), beating the consensus of $2.15.Merck revised and narrowed its full-year 2024 forecasts. The company expects 2024 sales of $63.4 billion—$64.4 billi ...

Key TakeawaysThe S&P 500 fell 0.5% on Tuesday, July 30, 2024, as tech stocks lost ground ahead of key earnings reports and a decision on interest rates from the Federal Reserve. Merck shares plunged after the pharmaceutical giant lowered its profit outlook to account for a one-time charge related to its EyeBio acquisition.Shares of Howmet Aerospace took off following strong quarterly results driven by robust demand for commercial aircraft components. Major U.S. equities indexes were mixed for the second str ...

Merck & Co., Inc. (NYSE:MRK) Q2 2024 Earnings Conference Call July 30, 2024 9:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean Li - President of Merck Research Labs Conference Call Participants Chris Schott - JPMorgan Umer Raffat - Evercore Carter Gould - Barclays Tim Anderson - Wolfe Research Steve Scala - TD Cowen Mohit Bansal - Wells Fargo Luisa Hector - Berenberg Dana Graybosch - Leerink Akash Tewari - Jefferies Trung Huynh - UBS Louise ...

Merck (MRK) reported adjusted earnings of $2.28 per share in second-quarter 2024, beating the Zacks Consensus Estimate of $2.16. In the year-ago period, management incurred an adjusted loss of $2.06. This reported loss was due to a one-time charge of $4.02 per share incurred by the company to acquire Prometheus Biosciences, which was completed in June 2023.Including acquisition and divestiture-related costs, restructuring costs, income and losses from investments in equity securities and certain other items ...

Merck & Co. Inc. NYSE: MRK delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year earnings forecast. The pullback comes as MRK stock is up 17% in 2024. If you look beyond the headline numbers, this could be a good buy-the-dip opportunity. MRK Merck & Co., Inc. Today Merck & Co., Inc. $115.88 -11.90 (-9.31%) 52-Week Range $99.14 ▼ $134.63 Dividend Yield 2.66% P/E Ratio 128.76 Price Target $135.36 Ad ...

Pharmaceutical giants Merck & Co Inc (NYSE:MRK) and Pfizer Inc (NYSE:PFE) today reported second-quarter results. While the former beat top- and bottom-line estimates thanks in part to cancer drug Keytruda sales, it also issued a dismal annual profit outlook. Pfizer beat earnings and revenue expectations as well, but lifted its guidance for the full year.  Merck stock is down 6.2% to trade at $119.89 at last check, gapping below the $120 level that contained June and March pullbacks. Shares are also on track ...

Merck (MRK) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $2.16 per share. This compares to loss of $2.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.56%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $1.94 per share when it actually produced earnings of $2.07, delivering a surprise of 6.70%.Over the last four quarters, the company ha ...